At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 23 enrolled
Drug / intervention
Nicotine +1 moredrug
Likely dose
Nicotine 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Simultaneous fMRI/EEG of the 4 mg Nicotine Lozenge in Relief of Cognitive Impairment Associated With Nicotine Withdrawal
In Brief
A Phase 4 clinical trial evaluating Nicotine and Placebo for Smoking. Completed, enrolled 23 participants.
Detailed Summary
A single center, double blind, randomized, placebo controlled, two-treatments, two-period crossover study conducted in adult smokers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
Primary CompletionFeb 2008
First PostedApr 2008
TodayJul 2026
First PostedApr 14, 2008
Enrollment StartSep 1, 2007
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.2 years ago
Interventions
Nicotinedrug
Nicotine lozenge containing 4 mg of nicotine
Placebodrug
Placebo lozenge